---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000007"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-02-23T23:59:59+00:00"
generated_at: "2026-06-05T16:54:18.398146+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Travere and CSL Vifor receive CHMP positive opinion for sparsentan in IgAN in EU

## Summary
- EMA CHMP recommended conditional marketing authorization for sparsentan for primary IgAN with proteinuria >1.0 g/day.
- Positive opinion based on Phase 3 PROTECT Study results; EC final decision pending.
- If approved, sparsentan would get CMA in all EU member states plus Iceland, Liechtenstein, Norway.
- Already marketed in US as FILSPARI under accelerated approval for proteinuria reduction.

## SEC filing metadata
- accession: 0001438533-24-000007
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-02-23T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000007/0001438533-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000007/tvtx-20240223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000007
- JSON: https://secwatch.observer/filing/0001438533-24-000007.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.